Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Independent Director Huang Min's 2025 Performance Report Released

China Visit Network data Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Baiyunshan” or the “Company”) recently released Independent Director Mr. Huang Min’s 2025 annual performance report. During the reporting period, Mr. Huang Min, as an independent director of the Company, strictly complied with relevant laws and regulations and the Company’s articles of association, and diligently and conscientiously performed his duties.

In terms of his performance overview, in 2025, Mr. Huang Min personally attended all 14 meetings of the board of directors and all 4 general meetings of shareholders, and participated in all meetings of the three independent director special meetings, as well as the audit committee, the nomination and remuneration committee, and the budget committee, with no instances of absence. He actively communicated with the Company’s management, the internal audit bodies, and the annual audit accounting firm, and conducted careful reviews of the Company’s periodic reports and financial information.

The report highlights Mr. Huang Min’s independent opinions on multiple key matters. He reviewed the related-party transactions in which the Company would increase capital to Guangzhou Baiyunshan Biotech Co., Ltd., a related party; participate in establishing an equity investment fund; and the expected related-party transactions for day-to-day business in 2026. He believed that the relevant transactions followed the principles of fairness, impartiality, and transparency, and did not impair the interests of the Company or its shareholders. Regarding the appointment of the accounting firm, he agreed to the Company’s reappointment of Dahxin Certified Public Accountants as the Company’s financial and internal control audit institution for 2025. For the matters related to director nominations, including nominating Mr. Cheng Hongjin, Mr. Tang Heping, and Mr. Chen Jiehui as candidates for executive directors of the Company’s ninth session of the board of directors, Mr. Huang Min reviewed and found that the candidates’ qualifications were legal and compliant and that the nomination procedures complied with regulations. In addition, he also expressed his approval of the Company’s remuneration plan for its directors and senior management for 2025.

In his report, Mr. Huang Min concluded that his performance in 2025 maintained a sufficient level of independence and effectively safeguarded the lawful rights and interests of the Company and all its shareholders, especially minority shareholders. Looking ahead to 2026, he stated that he will continue to fulfill his duties with diligence, provide advice for the board’s decisions, and promote the Company’s standardized and compliant operation.

A massive flow of information and precise analysis—available on the Sina Finance app